These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35837880)

  • 1. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
    Spekhorst LS; Bakker D; Drylewicz J; Rispens T; Loeff F; Boesjes CM; Thijs J; Romeijn GLE; Loman L; Schuttelaar ML; van Wijk F; de Graaf M; de Bruin-Weller MS
    Allergy; 2022 Nov; 77(11):3398-3407. PubMed ID: 35837880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Spekhorst LS; Boesjes CM; Loman L; Zuithoff NPA; Bakker DS; Kamphuis E; Kamsteeg M; Haeck IM; Oosting AJ; van Lumig PPM; van Lynden-van Nes AMT; Tupker RA; Flinterman A; Garritsen FM; Touwslager WRH; de Bruin-Weller MS; Schuttelaar MA; de Graaf M
    Br J Dermatol; 2023 Aug; 189(3):327-335. PubMed ID: 37177895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM; Kamphuis E; de Graaf M; Spekhorst LS; Haeck I; van der Gang LF; Loman L; Zuithoff NPA; Dekkers C; van der Rijst LP; Romeijn GLE; Oosting AJ; Gostynksi A; van Lynden-van Nes AMT; Tupker RA; van Tuyll van Serooskerken AM; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; Schuttelaar MA; de Bruin-Weller MS
    JAMA Dermatol; 2024 Oct; 160(10):1044-1055. PubMed ID: 39110432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
    Spekhorst LS; de Graaf M; Loeff F; Zuithoff NPA; Bakker D; Boesjes CM; Thijs J; Achten R; van Wijk F; Rispens T; de Bruin-Weller MS
    JAMA Dermatol; 2022 Dec; 158(12):1409-1413. PubMed ID: 36322072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
    Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
    Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
    Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
    J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
    Tsianakas A; Luger TA; Radin A
    Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 15. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
    Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
    Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
    Spekhorst LS; de Graaf M; Zuithoff NPA; van den Reek JMPA; Kamsteeg M; Boesjes CM; Romeijn GLE; Loman L; Haeck I; Oosting AJ; de Boer-Brand A; Touwslager WRH; Flinterman A; van Lynden-van Nes AMT; Gostynski AH; de Bruin-Weller MS; Schuttelaar ML
    JAMA Dermatol; 2022 Sep; 158(9):1048-1056. PubMed ID: 35947364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
    Patruno C; Fabbrocini G; Lauletta G; Boccaletti V; Colonna C; Cavalli R; Neri I; Ortoncelli M; Schena D; Stingeni L; Hansel K; Piccolo V; Di Brizzi V; Potenza C; Tolino E; Bianchi L; Manti S; De Pasquale R; Di Lernia V; Caminiti L; Galli E; Coppo P; Chiricozzi A; De Simone C; Guerriero C; Amoruso FG; Provenzano E; Leonardi S; Licari A; Marseglia GL; Palermo A; Di Pillo S; Russo D; Moschese V; Patella V; Peduto T; Ferreli C; Zangari P; Veronese F; Berti SF; Gruber M; Pezzolo E; Termine S; Satta R; Dragoni F; Esposito M; Fargnoli MC; Chiodini P; Vallone Y; di Vico F; Picone V; Napolitano M
    J Dermatolog Treat; 2023 Dec; 34(1):2246602. PubMed ID: 37580895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.